Ivonib (ivitinib) price in 2024

Ivosidenib is recognized as an excellent isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is frequently mutated and overexpressed in a variety of cancers. These mutations often lead to abnormal cell growth and uncontrolled proliferation. Ivonib targets and inhibits mutated IDH1, effectively blocking its enzymatic activity, thereby preventing further differentiation and development of cancer cells.

Since July 2018 Avosidenib has received accelerated approval from the US FDA due to its significant efficacy and is used to treat relapsed and refractory acute myeloid leukemia in adults. Subsequently, the drug's therapeutic scope was further expanded and it was approved for use in combination with azacitidine or alone for the treatment of elderly patients with newly diagnosed acute myeloid leukemia, as well as the treatment of adults with locally advanced or metastatic cholangiocarcinoma and relapsed or refractory myelodysplastic syndromes. It is worth noting that ivosidenib only showed significant efficacy in patients with susceptible IDH1 mutations.

In February 2023, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) gave a positive review to avosidenib and recommended that it be granted marketing authorization for the treatment of acute myeloid leukemia and cholangiocarcinoma. This recommendation was ultimately fully approved by the EMA in May 2023, further demonstrating the potential and value of ivosidenib in the treatment of these serious diseases.

Ivonib is currently on the market in China and has not yet been included in domestic medical insurance reimbursement items. The domestically marketed Avosidenib is the original research version, with a specification of 250mg*60 tablets. The price is about more than 90,000, which is quite expensive. Patients can learn about Avosidenib available overseas. It is understood that there are original and generic versions of Avosidenib available overseas. The price of the original version of Avosidenib available overseas is around 260,000 yuan; the generic version of Avosidenib launched overseas is marketed by Lucius in Laos, and its price is around 6,800 yuan. If you have more questions about ivonib, please consult a professional overseas medical consultant for more information.